Tag: Everolimus

In transplant recipients and cancer patients, the incidence of mTOR inhibitor-associated stomatitis (mIAS) can be as high as 60% [1.2.3]. Understanding 'What are the side effects of mTOR inhibitors?' is crucial for managing these powerful drugs used in oncology and immunosuppression [1.2.3, 1.7.4].

Pharmacological data shows that medication misspellings and sound-alike names are a frequent cause of confusion, and the search term "Elvis Tablet" is a prime example. While no medication exists with this exact name, the query often points to several real and very different drugs, including Evelis (Everolimus), Elivish (Amitriptyline), and Elvi (Levocetirizine).

Evercon 0.25, which contains the active ingredient everolimus, is a targeted therapy and immunosuppressant medication used for a diverse range of conditions, primarily concerning oncology and transplant medicine. Everolimus works by targeting a crucial protein called mTOR, which plays a pivotal role in regulating cell growth and division. This unique mechanism makes it effective for both slowing the proliferation of cancerous cells and suppressing the immune system to prevent organ rejection.